Veopoz

Veopoz is an antibody injection that treats CHAPLE disease, a rare genetic disorder causing protein loss and chronic intestinal inflammation. It works by blocking complement C5, helping to stabilize protein levels and reduce hospital visits in both children and adults.

Molecule Details :

  • Molecule Name :

    Pozelimab-Bbfg
  • Innovator :

    REGENERON PHARMACEUTICALS, INC.
  • Approval Date :

    18-Aug-23
  • Data Exclusivity Expiry :

    18-Aug-27
  • Market Exclusivity Expiry :

    18-Aug-35
  • Dosage Form :

    IV Infusion
  • Strength :

    400mg/2ml
  • Therapeutic Category :

    Immunomodulators
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA
  • 2026 :

    9
  • 2027 :

    66
  • 2028 :

    153
  • 2029 :

    232
  • 2030 :

    292
  • 2031 :

    332
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?